Serum paraoxonase activity and its relationship to diabetic complications in patients with non—insulin-dependent diabetes mellitus

Ikeda, Yukio; Suehiro, Tadashi; Inoue, Mari; Nakauchi, Yuh; Morita, Tatsuhito; Arii, Kaoru; Ito, Hiroyuki; Kumon, Yoshitaka; Hashimoto, Kozo

doi:10.1016/s0026-0495(98)90246-3

Cited by 141 publications

(87 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies indicate an association between PON1 polymorphisms and various diabetic complications, notably coronary disease (which seems to be more frequent in diabetic [42±47] than in non-diabetic populations [48±54]) as well as retinopathy [55,56], neuropathy [25] and nephropathy [57,58]. Our study suggests PON1 polymorphisms could reflect, and possibly contribute to abnormal glucose control and hence insulin resistance, a risk factor for these complications.…”

Section: Discussionmentioning

confidence: 60%

The paraoxonase PON1 promoter polymorphism C(-107)T is associated with increased serum glucose concentrations in non-diabetic patients

et al. 2001

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 60%

The paraoxonase PON1 promoter polymorphism C(-107)T is associated with increased serum glucose concentrations in non-diabetic patients

et al. 2001

View full text Add to dashboard Cite

“…PON1 knockout mice were unable to protect against the progression of atherosclerosis by feeding on a high fat and high cholesterol diet [4], and atherosclerotic lesion formation was decreased in PON1 transgenic mice [5]. We are included among researchers who have reported that PON1 activity is related not only to macroangiopathy, but also to microangiopathy, such as retinopathy and nephropathy in diabetic patients [6][7][8]. These reports indicate that PON1 has effects against oxidative disorders in vivo and also that it plays an important role in the suppression of the development and progression of atherosclerosis [9].…”

Section: Introductionmentioning

confidence: 99%

Pitavastatin induces PON1 expression through p44/42 mitogen-activated protein kinase signaling cascade in Huh7 cells

et al. 2009

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, this association was not confirmed in other studies (Ombres et al 1998;Sanghera et al 1998;Cao et al 1998;Herrmann et al 1996) or in a large meta-analysis (Wheeler et al 2004). In addition, low serum PON1 activity has been reported in several diseases, which are associated with accelerated atherosclerosis, including CHD, diabetes mellitus, hypercholesterolaemia and chronic renal failure (Mackness et al 1991b;Abbott et al 1995;Paragh et al 1998;Ikeda et al 1998;Datoine et al 1998). More recently, the PON1 activity phenotype has been shown to be a better predictor of CHD than that of PON1 genotypes .…”

Section: Introductionmentioning

confidence: 99%

Paraoxonase 1 status in the Thai population

et al. 2005

View full text Add to dashboard Cite

Human serum paraoxonase 1 (PON1), a highdensity lipoprotein (HDL)-associated enzyme, has been shown to reduce the oxidation of low-density lipoprotein (LDL) and HDL by degrading lipid peroxides. This property of PON1 accounts for its ability to protect against atherosclerosis. In this study, we identified four polymorphisms in both the coding (L55M and Q192R) and regulatory regions (T-108C and G-909C) of the human PON1 gene in 202 healthy Thai individuals and investigated the influence of these polymorphisms on serum PON1 activity towards three substrates, namely, paraoxon, phenylacetate and diazoxon. The PON1 L55M, Q192R and G-909C polymorphisms significantly affected the variation in serum PON1 activity towards paraoxon. Serum PON1 activity towards paraoxon was significantly different among the genotype groups, as follows: 55LL > 55LM/55MM, 192RR > 192QR > 192QQ and À909CC > À909CG > À909GG. The PON1 Q192R and G-909C polymorphisms also influenced the variation in serum PON1 activity towards diazoxon but in the opposite direction to the activity towards paraoxon. Only the PON1 L55M polymorphism was associated with significant variation in serum PON1 activity towards phenylacetate while the PON1 T-108C polymorphism had no significant effect on serum PON1 activity towards any substrate. We also found linkage disequilibrium among the polymorphic sites, including Q192R versus L55M, Q192R versus T-108C and Q192R versus G-909C. Serum PON1 activity towards both paraoxon and phenylacetate, but not diazoxon, was positively correlated with HDL cholesterol (HDL-C) and apo AI concentrations. None of the PON1 polymorphisms significantly affected serum lipid, lipoprotein or apolipoprotein concentrations. Our findings suggest that the physiological relevance of the PON1 polymorphisms is that they are associated with significant differences in serum PON1 activity, and the impact of PON1 polymorphisms on this activity is substrate-dependent.

show abstract

Serum paraoxonase activity and its relationship to diabetic complications in patients with non—insulin-dependent diabetes mellitus

Cited by 141 publications

References 14 publications

The paraoxonase PON1 promoter polymorphism C(-107)T is associated with increased serum glucose concentrations in non-diabetic patients

The paraoxonase PON1 promoter polymorphism C(-107)T is associated with increased serum glucose concentrations in non-diabetic patients

Pitavastatin induces PON1 expression through p44/42 mitogen-activated protein kinase signaling cascade in Huh7 cells

Paraoxonase 1 status in the Thai population

Contact Info

Product

Resources

About